Sangamo Therapeutics (NASDAQ:SGMO) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Sangamo Therapeutics (NASDAQ:SGMO) to a strong sell rating in a research note issued to investors on Saturday.

A number of other equities research analysts have also commented on SGMO. Barclays reiterated an “equal weight” rating and issued a $1.00 price target (down previously from $5.00) on shares of Sangamo Therapeutics in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.33.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO opened at $0.57 on Friday. The firm has a 50 day moving average price of $0.44 and a two-hundred day moving average price of $0.52. The stock has a market cap of $191.10 million, a P/E ratio of -1.29 and a beta of 1.29. Sangamo Therapeutics has a 52-week low of $0.36 and a 52-week high of $1.40.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.08). The business had revenue of $0.58 million during the quarter, compared to the consensus estimate of $34.40 million. Sangamo Therapeutics had a negative return on equity of 813.95% and a negative net margin of 331.28%. Analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd acquired a new position in Sangamo Therapeutics during the second quarter worth $28,000. World Investment Advisors increased its position in shares of Sangamo Therapeutics by 88.5% during the third quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 20,000 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth about $41,000. Engineers Gate Manager LP raised its holdings in shares of Sangamo Therapeutics by 101.7% in the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 44,078 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in Sangamo Therapeutics by 30.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 90,550 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 21,300 shares in the last quarter. 56.92% of the stock is owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.